Nienke A. G. Lankheet

Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment

Jurjen S. Lagas, Robert A.B. van Waterschoot, Vicky A.C.J. van Tilburg et al. · Clinical Cancer Research · 2009 · 171 citations

Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial

Marcus Quinkler, Sarah Johanssen, Nielka P. van Erp et al. · The Journal of Clinical Endocrinology & Metabolism · 2012 · 169 citations · Full text

Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration

Seng Chuan Tang, Jurjen S. Lagas, Nienke A. G. Lankheet et al. · International Journal of Cancer · 2011 · 155 citations

Neuro-oncology, Bbb Transporters, Chemoprevention Strategy +12

Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry

Nienke A. G. Lankheet, M. J. X. Hillebrand, Hilde Rosing et al. · Biomedical Chromatography · 2012 · 106 citations

Biological Mass Spectrometry, Gemini C18 Column, Pre-clinical Pharmacology +19

Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care

Nienke A. G. Lankheet, Lotte M. Knapen, Jan H.M. Schellens et al. · Therapeutic Drug Monitoring · 2013 · 104 citations